<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38278522</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1936-086X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>ACS nano</Title><ISOAbbreviation>ACS Nano</ISOAbbreviation></Journal><ArticleTitle>Synergistic Viro-chemoimmunotherapy in Breast Cancer Enabled by Bioengineered Immunostimulatory Exosomes and Dual-Targeted Coxsackievirus B3.</ArticleTitle><Pagination><StartPage>4241</StartPage><EndPage>4255</EndPage><MedlinePgn>4241-4255</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsnano.3c09491</ELocationID><Abstract><AbstractText>Breast cancer's immunosuppressive environment hinders effective immunotherapy, but oncolytic viruses hold promise for addressing this challenge by targeting tumor cells and altering the microenvironment. Yet, neutralizing antibodies and immune clearance impede their clinical utility. This study explored microRNA-modified coxsackievirus B3 (miR-CVB3), an innovative oncolytic virus, and its potential in breast cancer treatment. It investigated miR-CVB3's impact on immune-related proteins and utilized exosomes as both protective shields and delivery carriers. Results demonstrated miR-CVB3's capacity to reshape immune-related protein profiles toward a more immunostimulatory state and enhance exosome-mediated immune cell activation. Notably, cancer cell-released exosomes encapsulating miR-CVB3 (ExomiR-CVB3) maintained its antitumor cytotoxicity and bolstered its immunostimulatory effects. Moreover, ExomiR-CVB3 shielded miR-CVB3 from neutralizing antibodies and rapid immune clearance when it was systemically administered. Building on these findings, ExomiR-CVB3 was engineered with the AS1411 aptamer and doxorubicin (ExomiR-CVB3/DoxApt), enhancing therapeutic efficacy. This notable approach, combining genomic modification, aptamer surface decoration, and doxorubicin addition, demonstrated safe delivery of CVB3 to cancer cells. Comprehensive <i>in vitro</i> and <i>in vivo</i> analyses revealed selective breast cancer cell targeting, cell death induction, and significant immune cell infiltration within the tumor microenvironment while sparing healthy organs. In summary, this study highlights ExomiR-CVB3/DoxApt as a pioneering breast cancer treatment strategy adaptable for diverse cancer types, offering a potent and versatile approach to reshaping cancer immunotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bahreyni</LastName><ForeName>Amirhossein</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamud</LastName><ForeName>Yasir</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashraf Nouhegar</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jingchun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Honglin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7708-7840</Identifier><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Nano</MedlineTA><NlmUniqueID>101313589</NlmUniqueID><ISSNLinking>1936-0851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CVB3</Keyword><Keyword MajorTopicYN="N">breast cancer immunotherapy</Keyword><Keyword MajorTopicYN="N">exosomes</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword><Keyword MajorTopicYN="N">tumor targeting</Keyword></KeywordList><CoiStatement>The authors
declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>26</Day><Hour>20</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38278522</ArticleId><ArticleId IdType="pmc">PMC10851665</ArticleId><ArticleId IdType="doi">10.1021/acsnano.3c09491</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garrido-Cano I.; Adam-Artigues A.; Lameirinhas A.; Blandez J. F.; Candela-Noguera V.; Lluch A.; Bermejo B.; Sancenón F.; Cejalvo J. M.; Martínez-Máñez R.; Eroles P. Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy. ACS Appl. Mater. Interfaces 2023, 15, 38323.10.1021/acsami.3c07541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.3c07541</ArticleId><ArticleId IdType="pmc">PMC10436244</ArticleId><ArticleId IdType="pubmed">37549382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D. N.; Chaudhuri A.; Dehari D.; Shekher A.; Gupta S. C.; Majumdar S.; Krishnamurthy S.; Singh S.; Kumar D.; Agrawal A. K. Combination therapy comprising paclitaxel and 5-fluorouracil by using folic acid functionalized bovine milk exosomes improves the therapeutic efficacy against breast cancer. Life 2022, 12 (8), 1143.10.3390/life12081143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12081143</ArticleId><ArticleId IdType="pmc">PMC9410314</ArticleId><ArticleId IdType="pubmed">36013322</ArticleId></ArticleIdList></Reference><Reference><Citation>Tevaarwerk A. J.; Gray R. J.; Schneider B. P.; Smith M. L.; Wagner L. I.; Fetting J. H.; Davidson N.; Goldstein L. J.; Miller K. D.; Sparano J. A. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 2013, 119 (6), 1140–1148. 10.1002/cncr.27819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.27819</ArticleId><ArticleId IdType="pmc">PMC3593800</ArticleId><ArticleId IdType="pubmed">23065954</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisusi F. A.; Akala E. O. Drug combinations in breast cancer therapy. Pharmaceutical nanotechnology 2019, 7 (1), 3–23. 10.2174/2211738507666190122111224.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/2211738507666190122111224</ArticleId><ArticleId IdType="pmc">PMC6691849</ArticleId><ArticleId IdType="pubmed">30666921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehata A. K.; Singh V.; Vikas; Singh N.; Mandal A.; Dash D.; Koch B.; Muthu M. S. Chitosan-g-estrone Nanoparticles of Palbociclib Vanished Hypoxic Breast Tumor after Targeted Delivery: Development and Ultrasound/Photoacoustic Imaging. ACS Appl. Mater. Interfaces 2023, 15, 34343.10.1021/acsami.3c03184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.3c03184</ArticleId><ArticleId IdType="pubmed">37433149</ArticleId></ArticleIdList></Reference><Reference><Citation>Marelli G.; Howells A.; Lemoine N. R.; Wang Y. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Frontiers in immunology 2018, 9, 866.10.3389/fimmu.2018.00866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00866</ArticleId><ArticleId IdType="pmc">PMC5932159</ArticleId><ArticleId IdType="pubmed">29755464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.; Shen Y.; Wan X.; Hu X.; Cai W.-Q.; Wu Z.; Xin Q.; Liu X.; Gui J.; Xin H.-Y.; Xin H.-W. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. Journal of Translational Medicine 2023, 21 (1), 500.10.1186/s12967-023-04360-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04360-8</ArticleId><ArticleId IdType="pmc">PMC10369732</ArticleId><ArticleId IdType="pubmed">37491263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagara M.; Miyamoto S.; Itoh S.; Soda Y.; Tani K. Development of new oncolytic virotherapy targeting breast cancer using coxsackievirus B3. Anticancer Res. 2021, 41 (1), 81–89. 10.21873/anticanres.14753.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.14753</ArticleId><ArticleId IdType="pubmed">33419801</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A.; Hazini A.; Heimann L.; Kurreck J.; Fechner H. Coxsackievirus B3—its potential as an oncolytic virus. Viruses 2021, 13 (5), 718.10.3390/v13050718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050718</ArticleId><ArticleId IdType="pmc">PMC8143167</ArticleId><ArticleId IdType="pubmed">33919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.; Luo H. Development of group B coxsackievirus as an oncolytic virus: opportunities and challenges. Viruses 2021, 13 (6), 1082.10.3390/v13061082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061082</ArticleId><ArticleId IdType="pmc">PMC8227215</ArticleId><ArticleId IdType="pubmed">34198859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A.; Liu H.; Mohamud Y.; Xue Y. C.; Zhang J.; Luo H. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice. Cancer Letters 2022, 548, 215849.10.1016/j.canlet.2022.215849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2022.215849</ArticleId><ArticleId IdType="pubmed">35995138</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveldt C.; van den Ende J.; van Montfoort N. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?. Cytokine &amp; Growth Factor Reviews 2023, 70, 1.10.1016/j.cytogfr.2023.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2023.01.002</ArticleId><ArticleId IdType="pubmed">36732155</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispenzieri A.; Tong C.; LaPlant B.; Lacy M. Q.; Laumann K.; Dingli D.; Zhou Y.; Federspiel M. J.; Gertz M. A.; Hayman S.; et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 2017, 31 (12), 2791–2798. 10.1038/leu.2017.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.120</ArticleId><ArticleId IdType="pmc">PMC5656536</ArticleId><ArticleId IdType="pubmed">28439108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y.-C.; Zhang Y.-N.; Yang X.; Wang S.-B.; Hu P.-Y. Delivery systems for enhancing oncolytic adenoviruses efficacy. Int. J. Pharm. 2020, 591, 119971.10.1016/j.ijpharm.2020.119971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119971</ArticleId><ArticleId IdType="pubmed">33059014</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia M.; Luo D.; Dong J.; Zheng M.; Meng G.; Wu J.; Wei J. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. Journal of Experimental &amp; Clinical Cancer Research 2019, 38 (1), 408.10.1186/s13046-019-1410-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-019-1410-x</ArticleId><ArticleId IdType="pmc">PMC6749703</ArticleId><ArticleId IdType="pubmed">31533779</ArticleId></ArticleIdList></Reference><Reference><Citation>Reale A.; Calistri A.; Altomonte J. Giving oncolytic viruses a free ride: Carrier cells for oncolytic virotherapy. Pharmaceutics 2021, 13 (12), 2192.10.3390/pharmaceutics13122192.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13122192</ArticleId><ArticleId IdType="pmc">PMC8709025</ArticleId><ArticleId IdType="pubmed">34959474</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia B.; Liu Y.; Wang J.; Lu Q.; Lv X.; Deng K.; Yang J. Emerging role of exosome-shuttled noncoding RNAs in gastrointestinal cancers: from intercellular crosstalk to clinical utility. Pharmacol. Res. 2023, 195, 106880.10.1016/j.phrs.2023.106880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2023.106880</ArticleId><ArticleId IdType="pubmed">37543095</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu P.; Yin S.; Cheng H.; Xu W.; Jiang J. Engineered Exosomes for Drug Delivery in Cancer Therapy: A Promising Approach and Application. Curr. Drug Delivery 2023, 10.2174/1567201820666230712103942.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567201820666230712103942</ArticleId><ArticleId IdType="pubmed">37438904</ArticleId></ArticleIdList></Reference><Reference><Citation>Raguraman R.; Bhavsar D.; Kim D.; Ren X.; Sikavitsas V.; Munshi A.; Ramesh R. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Letters 2023, 558, 216093.10.1016/j.canlet.2023.216093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2023.216093</ArticleId><ArticleId IdType="pmc">PMC10025995</ArticleId><ArticleId IdType="pubmed">36822543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran N. H.; Nguyen D. D.; Nguyen N. M.; Tran C.; Nguyen Thi N. T.; Ho D. T.; Nguyen H.-N.; Tu L. N. Dual-targeting exosomes for improved drug delivery in breast cancer. Nanomedicine 2023, 18 (7), 599–611. 10.2217/nnm-2022-0328.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2022-0328</ArticleId><ArticleId IdType="pubmed">37194929</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X.; Wu W.; Jing D.; Yang L.; Guo H.; Wang L.; Zhang W.; Pu F.; Shao Z. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy. J. Controlled Release 2022, 343, 107–117. 10.1016/j.jconrel.2022.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.01.026</ArticleId><ArticleId IdType="pubmed">35077741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang M.; Chen X.; Du D.; Shi J.; Deng M.; Long Q.; Yin X.; Wang Y.; Rao L. SPION decorated exosome delivery of TNF-α to cancer cell membranes through magnetism. Nanoscale 2020, 12 (1), 173–188. 10.1039/C9NR05865F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9NR05865F</ArticleId><ArticleId IdType="pubmed">31803890</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G.; Huang A. C.; Zhang W.; Zhang G.; Wu M.; Xu W.; Yu Z.; Yang J.; Wang B.; Sun H.; et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 2018, 560 (7718), 382–386. 10.1038/s41586-018-0392-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0392-8</ArticleId><ArticleId IdType="pmc">PMC6095740</ArticleId><ArticleId IdType="pubmed">30089911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni B.; Kirave P.; Gondaliya P.; Jash K.; Jain A.; Tekade R. K.; Kalia K. Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. Drug Discovery Today 2019, 24 (10), 2058–2067. 10.1016/j.drudis.2019.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.06.010</ArticleId><ArticleId IdType="pubmed">31228614</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin L.; Liu X.; Shao X.; Feng T.; Xu J.; Wang Q.; Hua S. The role of exosomes in lung cancer metastasis and clinical applications: an updated review. Journal of Translational Medicine 2021, 19, 312.10.1186/s12967-021-02985-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02985-1</ArticleId><ArticleId IdType="pmc">PMC8287779</ArticleId><ArticleId IdType="pubmed">34281588</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong X.; Ga L.; Ai J.; Wang Y. Progress in cancer drug delivery based on AS1411 oriented nanomaterials. J. Nanobiotechnol. 2022, 20 (1), 57.10.1186/s12951-022-01240-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01240-z</ArticleId><ArticleId IdType="pmc">PMC8805415</ArticleId><ArticleId IdType="pubmed">35101048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bie L.; Wang Y.; Jiang F.; Xiao Z.; Zhang L.; Wang J. Insights into the binding mode of AS1411 aptamer to nucleolin. Frontiers in Molecular Biosciences 2022, 9, 1025313.10.3389/fmolb.2022.1025313.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.1025313</ArticleId><ArticleId IdType="pmc">PMC9574071</ArticleId><ArticleId IdType="pubmed">36262475</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi S.; Zhang X.; Zhang J.; Wang X.-y.; Bi S. Functional Nucleic Acids-Engineered Bio-Barcode Nanoplatforms for Targeted Synergistic Therapy of Multidrug-Resistant Cancer. ACS Nano 2023, 17, 13533.10.1021/acsnano.3c02009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.3c02009</ArticleId><ArticleId IdType="pubmed">37458477</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H.; Wang Z.; Mo Q.; Yang J.; Yang F.; Tang Y.; Liu J.; Li X. Framework Nucleic Acid-Based Multifunctional Tumor Theranostic Nanosystem for miRNA Fluorescence Imaging and Chemo/Gene Therapy. ACS Appl. Mater. Interfaces 2023, 15, 33223.10.1021/acsami.3c01611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.3c01611</ArticleId><ArticleId IdType="pubmed">37421332</ArticleId></ArticleIdList></Reference><Reference><Citation>Deepak K.; Vempati R.; Nagaraju G. P.; Dasari V. R.; Nagini S.; Rao D.; Malla R. R. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol. Res. 2020, 153, 104683.10.1016/j.phrs.2020.104683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104683</ArticleId><ArticleId IdType="pubmed">32050092</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane L.; Singh A.; Mattheolabakis G.; Suresh M.; Amiji M. M. Exosome mediated communication within the tumor microenvironment. J. Controlled Release 2015, 219, 278–294. 10.1016/j.jconrel.2015.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.06.029</ArticleId><ArticleId IdType="pubmed">26143224</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y.; Xiong S. Differential traits between microvesicles and exosomes in enterovirus infection. MedComm 2023, 4 (5), e384.10.1002/mco2.384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.384</ArticleId><ArticleId IdType="pmc">PMC10518433</ArticleId><ArticleId IdType="pubmed">37752943</ArticleId></ArticleIdList></Reference><Reference><Citation>Garmaroudi F. S.; Marchant D.; Hendry R.; Luo H.; Yang D.; Ye X.; Shi J.; McManus B. M. Coxsackievirus B3 replication and pathogenesis. Future microbiology 2015, 10 (4), 629–653. 10.2217/fmb.15.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.5</ArticleId><ArticleId IdType="pubmed">25865198</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L. J.; Muench H. A simple method of estimating fifty per cent endpoints. American journal of epidemiology 1938, 27 (3), 493–497. 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M. Selection of nonfastidious adenovirus species in 293 cells inoculated with stool specimens containing adenovirus 40. Journal of clinical microbiology 1985, 22 (2), 205–209. 10.1128/jcm.22.2.205-209.1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.22.2.205-209.1985</ArticleId><ArticleId IdType="pmc">PMC268359</ArticleId><ArticleId IdType="pubmed">2993350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A.; Liu H.; Mohamud Y.; Xue Y. C.; Fan Y. M.; Zhang Y. L.; Luo H. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy. BMC medicine 2023, 21 (1), 193.10.1186/s12916-023-02901-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02901-y</ArticleId><ArticleId IdType="pmc">PMC10210435</ArticleId><ArticleId IdType="pubmed">37226233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>